ArticleThe American journal of tropical medicine and hygiene2025
Severity of Primary and Secondary Dengue Virus 1 Infections: A Hospital-Based Study in Puerto Rico, 2012-2014.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional antibody responses and protection against symptomatic dengue.Communications medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is the most common mosquito-borne viral disease in humans. Although many dengue virus (DENV) infections are asymptomatic or produce only mild illness, DENV can occasionally cause severe and fatal disease. In this study, we compared the severity of primary and secondary DENV-1 infections among patients enrolled in a prospective, hospital-based, acute febrile illnesses surveillance system in Puerto Rico (2012-2014). Serum samples collected <7 days after symptom onset were tested for DENV-serotypes by a real time-polymerase chain reaction assay. The positive samples that were collected ≤5 days after onset were then tested by a DENV IgG antibody ELISA to classify primary (IgG negative) and secondary (IgG positive) infections. Overall, 720 dengue infections (679 DENV-1, 3 DENV-2, and 38 DENV-4) were diagnosed during the study period. Of the 679 DENV-1 patients, 595 were included in the study, 445 (75%) were classified as secondary infections, and 150 (25%) as primary infections. Among these patients, 150 (25%) were classified as severe dengue. Severe dengue occurred in 28% of secondary DENV-1 infections. Severe disease was also common among primary DENV-1 infections, including 27% with plasma leakage, 15% with severe dengue, and 9% requiring admission to the intensive care unit. Even though DENV-1 has caused thousands of cases in Puerto Rico, this is the first report describing DENV-1 as the cause of severe primary infection in this country. Although secondary DENV-1 infections have an increased risk for severe disease, it is important for clinicians to be aware that any individual with dengue should be considered at risk for severe dengue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.